Navigation Links
Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
Date:9/2/2007

A nanoparticle drug delivery system designed for brain tumour therapy has shown promising tumour cell selectivity in a novel cell culture model devised by scientists at The University of Nottingham. The project, conducted jointly by the Schools of Pharmacy, Biomedical Sciences and Human Development, will be featured in the September issue of the Experimental Biology and Medicine.

Therapy for brain cancers is particularly difficult for a number of reasons, including getting sufficient drug to the tumour and selectivity of drug action. Dr Martin Garnett, Associate Professor of drug delivery at the School of Pharmacy said: We are working on a number of new therapeutic approaches using nanoparticle drug delivery systems. However, understanding and developing these systems requires suitable models for their evaluation.

The nanoparticles used in this study were prepared from a novel biodegradable polymer poly (glycerol adipate). The polymer has been further modified to enhance incorporation of drugs and make the nanoparticles more effective.

Dr Terence Parker, Associate Professor in the School of Biomedical Sciences explained: The interaction of tumour cells with brain cells varies between different tumours and different locations within the brain. Using 3-dimensional culture models is therefore important in ensuring that the behaviour of cells in culture is similar to that seen in real life.

The work was mainly carried out by graduate student Weina Meng who formulated the fluorescently labelled nanoparticles and studied them in a variety of tumour and brain cell cultures. Her early studies showed faster uptake of nanoparticles into tumour cell cultures than normal brain cell cultures grown separately. This selectivity was only seen in 3-dimensional cultures and was the driving force to develop a more complex and representative model.

Tumour cell aggregates have been used as cell culture models of cancer cells for man
'/>"/>

Contact: Dr Martin Garnett
44-011-595-15045
University of Nottingham
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel antibiotic dressing developed for improved wound healing
3. A novel augmentation
4. Novel biopsy technique for prostate cancer
5. Novel computer model for breast cancer
6. Novel research on liver cancer
7. Novel way to fight cancer
8. Novel test for bowel cancer
9. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
10. Novel Therapy for Chronic Problem
11. Gene enchances radiation therapy - A novel approach to fight cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...rter financial results -, LAVAL, QC, July 25 /PRN...DAQ: DDSS) today announced that it will host a con... to discuss its second quarter 2008,financial resu... financial,results via news release at approximate...nce call by telephone, dial 416-646-3095 or,1-800-...
(Date:7/25/2008)...erweight or obese is not only a personal issue tha... issue that impacts other people in society. A new...eveals that the extra Medicare cost associated wit...ant financial burden on tax payers, costing up to ...current Medicare population. , The article,s fi...
(Date:7/25/2008)...Fourth Annual Physician On-Call Pay ...swire/ -- Sullivan, Cotter and Associates, Inc.,ha...on-call pay rates and,practices, the 2008 Physicia...th data from 132 healthcare organizations nationwi...ates paid for 33 physician specialty areas along,w...
(Date:7/25/2008)...ire/ -- Sagent Pharmaceuticals, Inc.,a privately-...nced that it,has launched amiodarone HCl injection...e treatment and prophylaxis of frequently recurrin...table ventricular,tachycardia -- a potentially lif...arone HCl injection will be available immediately ...
Breaking Medicine News(10 mins):Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3
...the initial mammogram immediately so any follow-up...t. Between 5 percent and 11 percent of all screeni...ome back for a follow-up mammogram. Many abnormal ...g they do not result in a breast cancer diagnosis ...
...CPR on heart attack victims found they regularly g...ed for by American Heart Association CPR standards... minute, the EMS personnel were delivering on aver...perventilate. Even after personnel were retrained ...
...ck to heart disease, say researchers based on rece...ore exercise, the risk can be significantly reduce...re atherosclerosis -- the deadly build-up of plaqu... -- in the arm and neck arteries of kids. Even tho...
...coronavirus. Similar viruses infect the pigs and o... 2002 and spread to more than two dozen countries ...mmer. // More than 8,000 people worldwide were sic... mongoose-like animals that are sold in live food ...
Other Medicine News:Health News:SARS vaccine shows promise in Animal Testing 2
(Date:7/23/2008)... Work with Protein Therapeutics that Mod...AMBRIDGE, Mass., July 23 /- Taligen T...a corporate growth plan with the,appointment of Ab...d the,establishment of its headquarters in Cambrid...D., a co-founder of the company who remains presid...
(Date:7/22/2008)...s Development Initiative bring MJFF,s,current acti...nuary 20,2009, NEW YORK, July 22 /PRNewswire-USN...ry of transformative treatments and a cure for Par...r Parkinson,s Research has awarded,$2.7 million in... awards,were granted under MJFF,s Therapeutics Dev...
(Date:7/22/2008)... and Apidra(R) Resulted in Significant, Reductions... the Algorithm Us...sults from the "Adjust to,Target in Type 2 Diabete...e,Counting for Adjustment of Mealtime Insulin Glul...tes Association,s (ADA) medical journal,Diabetes ...
(Date:7/22/2008)...umbia University Medical Center Based on ..., The Test Differentiates Squamous From Non-Squa...ing Squamous-Cell Carcinoma of the Lung With ...Percent,This is the First CLIA Approved Test Which...arkers for Accurate Diagnosis of Lung Cancer, REH...
Breaking Medicine Technology:Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Advanced Energy Consortium will develop micro and nanosensors to boost energy production 2605 1Advanced Energy Consortium will develop micro and nanosensors to boost energy production 2605 2Pelosi Democrats Host Health Care Forum This Morning 9587 1Pelosi Democrats Host Health Care Forum This Morning 9587 2Pelosi Democrats Host Health Care Forum This Morning 9587 3Pelosi Democrats Host Health Care Forum This Morning 9587 4Wisconsin Physicians Service Insurance Corporation Files Suit Against Aurora Health Care and HealthEOS 9583 1Wisconsin Physicians Service Insurance Corporation Files Suit Against Aurora Health Care and HealthEOS 9583 2The Widener University Elder Pennsylvanian Survey Finds Pennsylvanias Baby Boomers Anticipate Working Longer Retiring Later to Help Offset Looming He 9579 1The Widener University Elder Pennsylvanian Survey Finds Pennsylvanias Baby Boomers Anticipate Working Longer Retiring Later to Help Offset Looming He 9579 2The Widener University Elder Pennsylvanian Survey Finds Pennsylvanias Baby Boomers Anticipate Working Longer Retiring Later to Help Offset Looming He 9579 3The Widener University Elder Pennsylvanian Survey Finds Pennsylvanias Baby Boomers Anticipate Working Longer Retiring Later to Help Offset Looming He 9579 4
...monstrates Utility in Evaluating Drug,Efficacy; Dr... HDL,Therapy , ,PLEASANTON, CA, Mar 30, 2007 (MARK..., Inc. (NASDAQ: LIPD) Dr. H. Bryan Brewer, Jr.,Ch...oncluded from,the wide range of presentations at t...ting in New Orleans that the rationale for HDL,bei...
...: Time to Pay Attention to this,Overlooked Disease...-- During,National Sexually Transmitted Disease (S...is urging increased awareness of, and,testing for,...common curable STD in the United States. Awareness...at trich affects an estimated 7.4,million men and ...
Other Medicine Technology:Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 2Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 3Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 4Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 5Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million,Annually 2Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million,Annually 3
LigaSure system generator, bipolar only. Designed to permanently seal vessels and tissue bundles.
Sabre 180 is a powerful niche generator.
Sabre 180 is a powerful niche generator.
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator.
Medicine Products: